Boehringer Ingelheim Corporation Exits Hepatitis C Field, Pulls Regulatory Filings For Faldaprevir
6/23/2014 7:40:32 AM
Germany's Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus (HCV) therapies and has discontinued development of lead candidate faldepravir.
After a strategic review of its business, the company said it had elected to withdraw all regulatory filings for faldepravir - a protease inhibitor - because the "HCV treatment environment has significantly and rapidly evolved" in the last couple of years.
Help employers find you! Check out all the jobs and post your resume.
comments powered by